Michael D. Dalzell/Editing Samples



Managed care payers and manufacturers of biologic drugs are often perceived as having misaligned interests. But when good patient care becomes the focus of all involved, solutions follow. Both of the parties in this piece persevered through one obstacle after another to execute a pilot outcomes-based contract for a cancer therapy. In editing this essay, I worked with the authors to make it succinct, prevent it from becoming a litany of travails, and to keep the story flowing toward an honest and positive reflection about lessons learned.